文献速递淋巴瘤

局限期结节性淋巴细胞为主型霍奇金淋巴瘤的结局及PET适应策略的影响

Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach.
PubMed 文献 · Blood Adv · 2021-01-01

该研究基于BC Cancer数据,评估局限期NLPHL在常规放疗时代(1995-2005,n=36)和PET时代(2005年后,n=63)的结局。PET时代采用ABVD×4周期,若PET2阴性则单独化疗,阳性则改放疗。中位随访10.5年,5年PFS为91%,OS为97%,两时代无差异。

要点

  • 局限期NLPHL整体预后良好,5年PFS 91%、OS 97%。
  • PET2阴性者单独ABVD可能可行,需权衡急慢性毒性。
  • PET2阳性者5年PFS 80%,与阴性者无统计学差异。

核心结论

  • 局限期NLPHL患者预后良好,PET适应策略下单独ABVD可能为部分PET2阴性患者的选择。

研究设计与样本

  • 回顾性队列研究,基于BC Cancer数据,常规放疗时代36例,PET时代63例。

关键数值与推荐

  • PET2阴性者接受ABVD×4周期,阳性者改放疗;Deauville标准判读。

临床怎么用

  • 对局限期NLPHL可考虑PET2指导治疗,阴性者或可避免放疗。

局限性

  • 回顾性研究,样本量有限,PET2阳性者数量少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiotherapy (RT) is typically incorporated into the treatment of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), although it remains unknown whether chemotherapy alone may be suitable in select patients. We evaluated outcomes of limited-stage NLPHL at BC Cancer on the basis of era-specific guidelines: routine RT era, 1995 to 2005 (n = 36), combined modality with 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy followed by RT or RT alone; positron emission tomography (PET) era, after 2005 (n = 63), ABVD alone (4 cycles) if the PET scan after the second cycle of ABVD (PET2) is negative, or treatment is changed to RT if PET2 is positive. Median age of patients was 38 years (range, 16-82 years), 73% were male, and 43% had stage II. With a median follow-up of 10.5 years for all patients, 5-year progression-free survival (PFS) was 91% [corrected] and was 97% for overall survival (OS), with no difference by treatment era (PFS, P = .15; [corrected] OS, P = .35). For the 49 patients who had a PET2 scan, 86% were PET negative and 14% were PET positive by Deauville criteria with 5-year PFS rates of 92% and 80% (P = .87) [corrected], respectively. This is the largest study of a PET-adapted approach in NLPHL and supports that ABVD alone may be a viable option in select patients with a negative PET2 scan, with consideration of acute and long-term toxicities.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Cheng PTM, Villa D, Tonseth RP, et al. Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. Blood Adv. 2021. PMID: 34438445. doi:10.1182/bloodadvances.2021004375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。